Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.35 |
| ▸ | HRH1 | P35367 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621455 | 0.78 | GABRA1 (0.55) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL20621456 | 0.78 | GABRA1 (0.55) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL2649990 | 0.75 | SLC6A2 (0.41) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL725091 | 0.73 | SLC6A2 (0.54) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL28752820 | 0.73 | SLC6A2 (0.42) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL315614 | 0.72 | GABRA1 (0.50) | CYP1A2CYP3A4SLC6A2TSHRGABRA1 | |
| Ammonia Solution, Strong SCHEMBL7995788 | 0.71 | SLC6A2 (0.52) | CYP1A2CYP3A4KCNA5SLC6A2SLC6A4 | |
| SCHEMBL12475663 | 0.70 | TYR (0.58) | CYP1A2CYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1637966 | 0.70 | CHRM2 (0.39) | CYP1A2CYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL483577 | 0.69 | PARP1 (0.45) | CYP1A2CYP3A4SLC6A3TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060241110-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-10-26 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241110-A1 | Compounds, compositions, and methods | TNNI3, TNNT2, TNNC1 | CYP1A2 4607/4885CYP3A4 4637/4885KCNA5 2690/4885 |
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CYP1A2 4662/4885CYP3A4 4703/4885KCNA5 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.